{"id":"lvrna009","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an mRNA vaccine candidate, LVRNA009 delivers messenger RNA encoding target antigens that are translated by host cells to trigger both CD8+ T-cell and antibody-mediated immune responses. The vaccine approach leverages lipid nanoparticle formulation technology to facilitate cellular uptake and promote innate immune activation alongside adaptive immunity.","oneSentence":"LVRNA009 is an mRNA vaccine designed to stimulate immune responses against specific disease targets through encoded antigen expression.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:51.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05352867","phase":"PHASE2","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People","status":"COMPLETED","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2022-03-16","conditions":"SARS-CoV-2","enrollment":420},{"nctId":"NCT05682638","phase":"PHASE3","title":"A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-01-30","conditions":"SARS-CoV-2","enrollment":34000},{"nctId":"NCT05428592","phase":"PHASE3","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-04","conditions":"SARS-CoV-2","enrollment":1100},{"nctId":"NCT05364047","phase":"PHASE1","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine in China","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2021-07-31","conditions":"COVID-19","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LVRNA009","genericName":"LVRNA009","companyName":"AIM Vaccine Co., Ltd.","companyId":"aim-vaccine-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}